ArticleJournal of materials science. Materials in medicine2026
In vitro tolerability of soluble silicic acid and tetraethyl orthosilicate in ocular epithelial cells.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Biodegradable silica microparticles (SiMPs) are a promising carrier matrix for controlled ocular drug delivery. In tissues, SiMPs degrade into silicic acid (SiA), a soluble inorganic weak acid. This study evaluated the in vitro toxicity and tolerability of SiA and SiMPs' precursor, tetraethyl orthosilicate (TEOS), in human corneal epithelial cells (HCE-2) and retinal pigment epithelial cells (ARPE-19). Cells were exposed to serial dilutions of SiA and TEOS. Cell viability was assessed after 24, 48, and 72 h using the alamarBlue assay, while membrane integrity was analyzed through LDH release. To evaluate cellular stress from SiA and TEOS, levels of pro-inflammatory, apoptosis, and heat shock stress response markers were measured. Neither viability assay revealed significant differences in survival rates between the control group and 30 µg/mL SiA in ARPE-19 and HCE-2 cells at all time points. ARPE-19 viability decreased with low SiA concentrations, but this was not supported by LDH release or caspase-3 activation. Inflammatory markers IL-6, IL-8, and MCP-1 secretion or heat shock protein 70 expression levels were not changed in either cell line in response to SiA. Conversely, TEOS reduced cell viability at high concentrations (0.6-2.4 mg/mL) and affected the cytokine response in both cell lines. Our results indicate that both cell lines can tolerate SiA concentrations up to 30 µg/mL. In contrast, TEOS showed toxicity at concentrations above 0.6 mg/mL, which greatly exceeds expected levels in the SiMP formulation. These findings support the use of SiMPs as drug delivery vehicles in ophthalmic formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.